Recent Advances in Cancer Therapy

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across cancer therapy. Stem cell therapies, check-point inhibitors, and other novel biomarkers are illustrated through the most recent innovations in immuno-oncology. A summary of industry-funded clinical trials for stem cell therapy in blood cancers is also presented.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, c

Table of Contents

Recent Advances in Cancer TherapyInnovations in Cancer TherapyLeveraging Umbilical Cord Stem Cells for Treating Blood CancersCombining Checkpoint Inhibition with Immune Activation for Enhanced Cancer TherapyNovel Immunotherapy that Leverages Anti-inflammatory FunctionsLeveraging Predictive Biomarkers for Precision Oncology ApplicationsClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions




Related Subscription

• One-2-One Analyst briefing call •
• Access to published and new research deliverables •
• Mid year service review •
• Virtual Analyst briefing •
• GIL conference seats •

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.